Literature DB >> 15951979

Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin as a circuit coating material.

Hitoshi Izuha1, Momoe Hattori, Tsuguo Igari, Daiki Wakamatsu, Mdtoshiki Watanabe, Hitoshi Yokoyama.   

Abstract

At present, there are various biomaterials that have high biocompatibility. In particular, there are many types of coated circuits in cardiopulmonary bypass (CPB) systems. However, only a few clinical studies have investigated platelet aggregation caused by these coated circuits. In this study, a CPB system coated with poly-2-methoxyethylacrylate (X coating) was used to ascertain whether platelet aggregation could be suppressed during CPB, and a comparison was made between X coating and ordinary (covalently bonded) heparin coating. The subjects were 19 adult patients who were scheduled to undergo valve replacement or valvuloplasty. They were divided into two groups: group X (X coating) and group H (heparin coating). The platelet aggregation threshold index (PATI, grading curve) and beta-thromboglobulin and plalelet factor IV levels were assessed preoperatively (control), 5 min after heparin administration, 10 and 60 min after the start of CPB, and 0 and 2 h after the end of CPB. The results indicated that platelet aggregation was reduced during CPB and that platelets were activated. The changes in platelet aggregation associated with the X coating were shown to be similar to those associated with heparin coating.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951979     DOI: 10.1007/s10047-004-0280-x

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  6 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children.

Authors:  D Journois; D Israel-Biet; P Pouard; B Rolland; W Silvester; P Vouhé; D Safran
Journal:  Anesthesiology       Date:  1996-11       Impact factor: 7.892

3.  The influence of cardiopulmonary bypass on the size of human platelets.

Authors:  N Laufer; G Merin; N B Grover; B Pessachowicz; J B Borman
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

4.  [A clinical study on hemostatic fluctuation during and after cardiopulmonary bypass using hemostatic molecular markers].

Authors:  H Nakajima
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1992-11

5.  Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations.

Authors:  M Seghaye; J Duchateau; J Bruniaux; S Demontoux; C Bosson; A Serraf; G Lecronier; E Mokhfi; C Planche
Journal:  J Thorac Cardiovasc Surg       Date:  1996-03       Impact factor: 5.209

6.  [A novel whole blood aggregometer].

Authors:  Ruriko Konishi; Norimasa Seo
Journal:  Masui       Date:  2003-01
  6 in total
  3 in total

1.  Trends and emerging technologies in extracorporeal life support: results of the 2006 ECLS survey.

Authors:  Alicia N Sievert; Anthony G Shackelford; Mary M McCall
Journal:  J Extra Corpor Technol       Date:  2009-06

2.  Poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit can reduce transfusion of platelet products compared to heparin-coated circuit during aortic arch surgery.

Authors:  Katsuhiro Hosoyama; Koki Ito; Shunsuke Kawamoto; Kiichiro Kumagai; Masatoshi Akiyama; Osamu Adachi; Satoshi Kawatsu; Konosuke Sasaki; Marina Suzuki; Yumi Sugawara; Yuya Shimizu; Yoshikatsu Saiki
Journal:  J Artif Organs       Date:  2016-02-24       Impact factor: 1.731

Review 3.  Novel Surfaces in Extracorporeal Membrane Oxygenation Circuits.

Authors:  Andrea Ontaneda; Gail M Annich
Journal:  Front Med (Lausanne)       Date:  2018-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.